Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy

Key Takeaways NVO filed for FDA approval of a 7.2 mg Wegovy dose using the agency's CNPV pilot program.The STEP UP study showed 20.7% average weight loss with the 7.2 mg dose over 72 weeks.One-third of patients on the 7.2 mg dose achieved at least 25% weight loss in the study.Novo Nordisk (NVO) announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectable semaglutide).The FDA filing seeks approval for a 7.2 mg dose of the dr ...